denkapparat Operations GmbH Acquires 508 Shares of argenex SE $ARGX

denkapparat Operations GmbH increased its holdings in argenex SE (NASDAQ:ARGX) by 126.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 910 shares of the company’s stock after buying an additional 508 shares during the quarter. denkapparat Operations GmbH’s holdings in argenex were worth $844,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Janus Henderson Group PLC increased its holdings in argenex by 3.4% during the first quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock valued at $1,847,592,000 after buying an additional 83,568 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of argenex by 80.1% during the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after acquiring an additional 324,653 shares during the last quarter. Morgan Stanley grew its position in shares of argenex by 19.2% during the 4th quarter. Morgan Stanley now owns 518,852 shares of the company’s stock valued at $436,331,000 after acquiring an additional 83,746 shares during the period. Invesco Ltd. grew its position in shares of argenex by 390.4% during the 4th quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock valued at $350,178,000 after acquiring an additional 331,489 shares during the period. Finally, Sands Capital Management LLC increased its stake in shares of argenex by 2,046.6% in the 4th quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock worth $300,110,000 after purchasing an additional 340,245 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors.

argenex Stock Performance

Shares of ARGX stock opened at $1,053.46 on Friday. The stock has a fifty day simple moving average of $923.55 and a two-hundred day simple moving average of $840.13. The firm has a market capitalization of $65.90 billion, a PE ratio of 40.46, a PEG ratio of 1.09 and a beta of 0.47. argenex SE has a 52-week low of $661.85 and a 52-week high of $1,072.75.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Tuesday, July 21st. The company reported $7.32 EPS for the quarter, beating the consensus estimate of $5.86 by $1.46. argenex had a return on equity of 43.59% and a net margin of 32.19%.The business had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.45 billion. On average, sell-side analysts forecast that argenex SE will post 29.13 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. HC Wainwright raised their target price on argenex from $940.00 to $1,202.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Citigroup upped their price target on argenex from $1,152.00 to $1,182.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Wells Fargo & Company raised their price objective on argenex from $1,350.00 to $1,415.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 26th. Citizens Jmp lifted their price objective on argenex from $932.00 to $1,200.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 18th. Finally, Truist Financial boosted their price objective on argenex from $1,030.00 to $1,095.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,158.61.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.